Biomarker Technology Platforms for Cancer Diagnoses and Therapies 2014

Description: Until superior therapeutic treatments are developed to prevent, treat and cure cancer, the best means of reducing mortality and morbidity in a disease this complex is early detection and diagnosis. In the major solid cancer types such as lung, breast, colon and prostate, long-term survival rates drop precipitously once metastasis has occurred. The case is clear for development of biomarkers for early detection and screening tests for diseases such as breast, colon, ovarian and lung cancer.

In addition, diagnostic measurement of cancer disease progression is essential to successful disease management. For these reasons, development of new and effective biomarkers for cancer detection and diagnosis is central to the cancer problem. The use of nucleic acid biomarker diagnostics have begun to answer these questions. Protein biomarkers are also useful.

The purpose of this publications report is to describe the specific segment of the cancer diagnostics market which develops new biomarker technology platforms for diagnosing and treating cancer. Biomarkers are useful in following the course of cancer and evaluating which therapeutic regimes are most effective for a particular type of cancer, as well as determining long-term susceptibility to cancer or recurrence.

This study particularly examines those clinical measurement devices, and their reagents and supplies, which are meant to be used in hospitals, clinics, commercial laboratories and doctor’s offices to diagnose and monitor cancer. The examination also provides an in-depth discussion of the application of biomarkers in developing novel targeted cancer therapeutics, their predication response and efficacy, as well as their use in diagnosis of cancer.

Contents: 1. Overview
1.1 Statement of Report
1.2 About This Report
1.3 Scope of the Report
1.4 Objectives
1.5 Methodology
1.6 Executive Summary
2. Introduction to Cancer Biology and the Diagnostic Industry
2.1 Biomarkers
2.1.1 The Biomarker Market for Cancer and Key Sectors
2.1.1.1 The Sector
2.1.1.2 The Critical Path Opportunities
2.1.1.3 Capital Markets
2.1.1.4 Molecular Diagnostics Technology Platforms
2.2 Cancer Detection and Treatment Using Biomarkers as a Guide
2.2.1 The Problem
2.3 Next Generation Sequencing and Biomarker Discovery
2.3.1 Second-Generation Sequencing
2.3.2 Whole Genome Sequencing (WGS)
2.3.3 Epigenomics
2.3.4 Bioinformatics and Next Generation Sequencing
2.3.5 Third Next Generation Sequencing
3. Market Analysis of the Cancer Biomarkers Space
3.1 Scope of This Chapter
3.2 The Overall Market Opportunity and Segmentation of the Total Cancer Biomarkers Marketplace
3.3 Potential Cancer Biomarker Commercial Applications
3.3.1 Market for Routine Tumor Markers
3.3.2 PSA Testing Market Size
3.3.3 Market Size and Forecasts for Companion Diagnostic Tests for Cancer Therapeutics
3.3.4 SWOT Analysis of the Major Cancer Biomarker Market Segments
3.3.4.1 Traditional Serum Cancer Biomarkers
3.3.4.2 Proteomic Cancer Biomarkers
3.3.4.3 Companion Diagnostic Cancer Biomarkers
3.4 Cancer Biomarker Market Estimates by Tissue of Origin
3.4.1 Colorectal
3.4.2 Prostate
3.4.3 Lung
3.4.4 Breast
3.4.5 Ovarian
3.5 Challenges Facing Cancer Biomarker Developers
3.6 Unmet Product Needs in the Cancer Biomarkers Space
3.7 Epigenic Markers for Cancer
3.8 Molecular Diagnostics Testing for Cancer
3.9 Market Opportunities
3.9.1 Industry Overview
3.9.2 Medical Indications and Medically Useful Information
3.9.3 Research Market
3.9.4 Competition
3.9.5 Diagnostic Services
3.9.6 Clinical Image Analysis
3.9.7 Research Imaging Market
3.9.8 Genomic Disease Management and In Vitro Diagnostic Multivariate Index Assays (IVDMIA)
3.9.9 Predictive Expression Profiles

4. Major Clinical Applications of Cancer Biomarkers
4.1 Launched Products and Pipeline
4.2 Launched Products and Pipeline
4.3 CYP2C9 Pharmacogenetics and Role in Personalized Medicine
4.4 Personalized Breast Cancer Therapy
4.5 Personalized NSCLC Therapy
4.6 AmpliChip-Based Personalized Medicine

5. Breast Cancer
5.1 Overview of Breast Cancer Disease
5.2 Incidence and Mortality Rates
5.2.1 Incidence Rates
5.2.2 Mortality Rates
5.3 BRCA1 and BRCA2 Genes
5.3.1 Types of Genetic Testing Available for Breast Cancer
5.3.1.1 DNA Sequencing
5.3.1.2 Multi-Site Analysis
5.3.1.3 Single-Site Analysis
5.3.2 BRCA Test Results
5.3.2.1 What Does a Positive BRCA1 or BRCA2 Test Result Mean?
5.3.2.2 What does a Negative BRCA1 or BRCA2 Test Result Mean?
5.3.2.3 What does an Ambiguous BRCA1 or BRCA2 Test Result Mean?
5.3.2.4 What are the Options for a Person who Tests Positive?
5.3.3 What are Some of the Benefits of Genetic Testing for Breast Cancer Risk?
5.3.4 What are Some of the Risks of Genetic Testing for Breast and Ovarian Cancer Risk?
5.4 Estrogen Receptors and Breast Cancer
5.4.1 Expression and Prognostic Value of ER
5.4.2 Progesterone Receptors and Breast Cancer
5.4.3 ER and PR Predict Response to Endocrine Therapy
5.5 HER2 Gene and Protein
5.5.1 HER2 Tests
5.5.1.1 IHC Test
5.5.1.2 FISH Test
5.5.1.3 Questions About Testing
5.5.1.4 HER2 Tumor Status
5.6 Herceptin Treatment
5.7 Tumor Assays for Adjuvant Chemotherapy
5.8 Use of Genomics to Understand Breast Cancer
5.9 Genetic Analysis Solution
5.9.1 The Use of Proteomics in Breast Cancer
5.9.2 Tissue Microarrays
5.9.3 Protein Microarrays
5.10 Gene Expression Microarrays and Recurrence Prediction
5.10.1 Oncotype DX
5.10.2 Oncotype DX for Breast Cancer
5.10.3 Risk Assessment
5.10.4 Use of Chemotherapy
5.10.5 Utility of the Oncotype DX Test
5.10.6 Clinical Development and Validation of Oncotype DX
5.10.6.1 Clinical Development of the Oncotype DX Recurrence Score
5.10.6.2 Clinical Validation of Prediction of Recurrence and Survival in N-, ER+ Patients Treated with Tamoxifen
5.10.6.3 Oncotype DX Predicts the Likelihood of Recurrence
5.10.6.4 Oncotype DX Predicts the Likelihood of Breast Cancer Survival in a Community Hospital Setting
5.10.6.5 Oncotype DX Predicts both Prognosis and Tamoxifen Benefit
5.11 Economic Benefits of Oncotype DX
5.12 Increased Clinical Utility of Oncotype DX
5.13 Second Generation Oncotype DX
5.13.1 Recurrence and Benefit Test for N-, ER- Breast Cancer
5.13.2 Taxane Benefit Test
5.14 MammaPrint
5.15 Rotterdam Signature 76-Panel
5.16 Summary of Microarray Technologies
5.17 Mass Spectrometry-Based Approaches
5.17.1 Gel-Based Approaches
5.17.2 Non-Gel-Based Approaches
5.17.2.1 SELDI-TOF MS
5.17.2.2 SELDI and Prognosis
5.17.2.3 SELDI and Treatment Monitoring
5.18 Outlook
5.19 Future Perspectives
5.20 Breast Cancer Program (NMP66)
5.21 Myriad Genetics
5.22 Janssen Diagnostics, LLC GeneSearch Breast Lymph Node
5.23 OncoVue® Cancer Risk Test (InterGenetics, Inc.)
5.24 Research Biomarkers for Breast Cancer
5.25 Protein Biomarkers for Breast Cancer Prevention
5.26 Biomarker Prognosis of Breast Cancer Treated with Doxorubicin

6. Ovarian Cancer
6.1 Incidence Rates
6.1.1 Incidence Rates
6.1.2 Mortality Rates
6.2 Serum Markers
6.3 Biomarkers
6.3.1 Strategies for Discovering New Cancer Biomarkers
6.4 Serum Protein Biomarkers for Ovarian Cancer
6.4.1 Clinical Proteomics
6.5 Ovarian Cancer Triage Testing
6.5.1 Vermillion's Ovarian Cancer Triage Diagnostic Program

7. Prostate Cancer
7.1 Overview
7.1.1 Incidence Rates
7.1.2 Mortality Rates
7.1.3 Prostate Cancer Progression and Recurrence Test
7.1.4 Current Market Size
7.2 Genes Involved in Prostate Cancer
7.3 Androgen Independence
7.4 Gene Markers in Prostate Cancer
7.5 Microarray Gene Identification of Prostate Biomarkers
7.6 GEArray DNA Microarrays
7.7 Vermillion's Cancer Diagnostic Program
7.8 Hepsin
7.9 Hologic Gen-Probe's PCA3 Assay
7.10 Early Prostate Cancer Antigen-2 (EPCA-2)
7.11 New and Novel Methods for Detection of Prostate Cancer
7.12 Mass Spectrometry
7.13 Summary

8. Bladder Cancer
8.1 Overview
8.2 Incidence and Mortality Rates
8.2.1 Incidence Rates
8.2.2 Mortality Rates
8.3 Progression and Recurrence
8.3.1 Bladder Cancer Risk Factors
8.3.2 Bladder Cancer Symptoms
8.4 Bladder Cancer Tests
8.5 UroVysion Bladder Cancer Kit (Abbott Molecular)
8.6 The oncoFISH Bladder (Ikonisys)
8.6.1 The CellOptics Platform (Ikonisys)
8.6.2 Cell Staining and Genetic Characterization
8.6.3 Ikoniscope/IkoniLAN Automated Microscopy
8.7 Nuclear Matrix Protein Markers
8.8 ImmunoCyt/uCyt+
8.9 Bladder Cancer Market
8.9.1 Urologist Market
8.9.2 Clinical Lab Market
8.9.3 Primary Care Market
8.9.4 Private and Public Sector Markets
8.9.5 POC Market
8.9.6 Market Distribution
8.9.7 Reimbursement

9. Colorectal Cancer
9.1 Overview
9.2 Incidence and Mortality Rates
9.2.1 Incidence Rates
9.2.2 Mortality Rates
9.2.3 Progression and Recurrence
9.3 Screening for CRC
9.4 Almac Diagnostics DSA
9.5 Colon Cancer Program (NMP35)
9.6 Myriad Genetics COLARIS AP Risk Assessment
9.7 Summary

10. Genetic Diagnostics Set to Revolutionize Cancer Diagnostic Testing
10.1 Overview
10.1.1 Clinicians' Need for More Information with Regard to Therapeutic Treatment Drives Demand for Pharmacogenomic Testing
10.1.2 Predictive Medicine Shows Potential for Genetic Diagnostics
10.1.3 Different Rates of Growth
10.1.4 Effective Competitive Strategies
10.1.5 Improvements in Marketing Effectiveness
10.1.6 Emerging Technologies Imply Start of a New Era and Offer Tremendous Growth Opportunities
10.1.7 Increased Market Share
10.1.8 Technologies Used in Genetic Testing
10.2 AMAS Test
10.3 Corixa (now GSK) Antibodies as Tumor Markers
10.4 CytoVision
10.5 Ariol System
10.6 Mammaglobin Protein Expression
10.7 L523S or KOC RNA Binding Protein
10.8 CA1-18 from EDP Biotech Corporation

11. Leukemia Biomarkers
11.1 Overview
11.2 Incidence and Mortality Rates
11.2.1 Incidence Rates
11.2.2 Mortality Rates
11.3 Progression and Recurrence

12. Lung Cancer
12.1 Introduction
12.2 Incidence and Mortality Rates
12.2.1 Incidence Rates
12.2.2 Mortality Rates
12.3 Lung Cancer Diagnostic Tests

13. Enabling Technologies for Oncology Biomarker Discovery
13.1 Automated Cellular Imaging System (ACIS III)
13.1.1 ACIS for HER2 Protein Expression Testing
13.1.2 ACIS for ER Protein Expression Testing
13.1.3 ACIS for PR Protein Expression Testing
13.1.4 ACIS for Cell Proliferation Expression
13.1.5 ACIS for Protein Expression
13.1.6 ACIS for Protein Micrometastases in Bone Marrow
13.1.7 ACIS for Protein Micrometastases in Tissue
13.1.8 ACIS for TMA
13.1.9 ACIS for DNA Ploidy
13.1.10 ACIS for HPV
13.2 DNA Methylation
13.2.1 Differential Methylation Hybridization (DMH)
13.2.2 MIRA-Assisted Microarrays for DNA Methylation Analysis and Cancer Diagnosis
13.3 Proteomics
13.3.1 Proteomics Technologies for Cancer Marker Discovery
13.3.2 Validation of Candidate Biomarkers
13.3.3 Requirements Bringing a New Marker into the Market
13.3.4 Value Chain in the Development of New Cancer Biomarkers
13.4 Secreted Proteins as Cancer Biomarkers
13.4.1 Markers of Known Tissue Origin
13.4.2 Secreted Proteins as Low Abundance Markers
13.4.3 Secreted Proteins in Tissue and Blood
13.5 Non-coding RNAs as Potential Tumor Markers
13.5.1 miRNA Meets Microarray
13.5.2 Mimetics and Inhibitors
13.5.3 Clinical Patterns in Cancer
13.6 Architect TIMP-1 (Tissue Inhibitor of Metalloproteinases-1) Immunoassay for CRC Detection
13.7 Companies Developing Automated Microscope-Based Analysis Systems
13.8 Companies Developing Research Products for Tumor Cell Isolation
13.9 Companies Supplying Fluorescently Labeled Antibodies to Characterize Tumor Cells
13.10 PerkinElmer High-Throughput Platforms: AlphaScreen, AequoScreen, DELFIA and LANCE Technologies

14. Biomarker Tests Co-Developed with Cancer Therapeutics as Companion Diagnostics
14.1 Sector Overview
14.2 Companion Diagnostics
14.3 EGFR for CRC and Camptostar (Irinotecan)
14.3.1 Companion Diagnostic Test Developed for UGT1A1 for Irinotecan
14.3.2 Companion Diagnostic Test Developed for Bristol-Myers' SPRYCEL
14.3.3 EGFR Express and Erbitux (Cetuximab)
14.4 Companions Based on Myriad's IVDMIA Technology
14.4.1 Myriad's TheraGuide 5-Fluorouracil (5-FU)
14.4.2 BRACAnalysis Test
14.5 Companions for Tyrosine Kinase Inhibitors: Erlotinib and Gefitinib
14.5.1 TheraScreen: EGFR29
14.5.2 The K-RAS Mutation Detection Kit
14.8 Drivers and Barriers to Companion Diagnostics

14.9 Partnerships with Pharma Companies to Identify Therapeutic Targets

14.10 Future Developments for Companion Diagnostics

15. Companion Diagnostics and Personalized Medicine: Biology, Approaches, Pipeline and Regulatory Trends

15.1 Scope of This Chapter

15.2 Introduction to Companion Diagnostics and Personalized Medicine

15.2.1 Stakeholders in Companion Diagnostics

15.2.2 Development of Stakeholders' Business Models for Companion Diagnostics for Personalized Medicine

15.2.2.1 Pharmaceutical Company Business Models for Developing Companion Diagnostics Products

15.2.2.2 Diagnostic Company Business Models for Developing Companion Diagnostics Products

15.2.2.3 Life Science Company Business Models for Developing Companion Diagnostics Products

15.2.2.4 Pharmacy Benefit Management Company Business Models for Developing Companion Diagnostics Products

15.2.3 Trends in Companion Diagnostic Deals

15.2.3.1 Market Size of Companion Diagnostics

15.2.4 Companion Diagnostics: Industry SWOT Analysis

15.2.5 Challenges for Companion Diagnostics Development

15.2.6 Timeline for Impact of Various Segments in Companion Diagnostics

15.2.7 Use of Proteomics to Develop Individualized Tests

15.3 The Compelling Case for Personalized Medicine

15.4 Drug Metabolism and Implications for Companion Diagnostics and Personalized Medicine

15.5 Examples of Personalized Medicine

15.6 Personalized Medicine and Companion Diagnostics Testing Product Pipeline

15.7 The Personalized Medicine Coalition

15.8 Regulatory Trends and Guidelines in the Personalized Medicine Space

15.8.1 The Changing Regulatory Landscape for Personalized Medicine

15.9 Patenting Personalized Medicine

15.10 The Leading Edge of Personalized Medicine: Specific Examples of Clinical Situations Where Personalized Medicine and Companion Diagnostics are Appropriate and Being Deployed

15.10.1 EGFR Assay

15.10.2 UGT1A1 Molecular Assay for Camptosar

15.10.3 Response to Gleevec in Gastrointestinal Stromal Tumors

15.10.4 LabCorp and Qiagen and Personalized Medicine for the treatment of Colorectal Cancer

15.10.5 Labcorp and ARCA Discovery, Inc. and Personalized Medicine for Cardiovascular Disease

15.11 Companion Diagnostics and Personalized Medicine: Qualitative and Quantitative Market Analysis

15.11.1 Market Analysis of Molecular Diagnostics and Companion Diagnostics and Personalized Medicine

15.11.2 Diagnostics vs. Pharmaceuticals

15.11.3 Molecular Diagnostic Market

15.11.4 Molecular Diagnostics Technology Platforms and their Impact on Personalized Medicine

15.12 Snapshot of Companion Diagnostics Industry Structure

15.13 The Case for Theranostics (Therapeutic/Companion Diagnostic)

15.14 Personalized Medicine Market Analysis—Market Survey Data Characterizing the Qualitative and Quantitative Industry Parameters

15.15 How the Market Segregates Today

15.16 Timeline for Impact of Various Segments in Personalized Medicine

15.17 Challenges for Personalized Therapeutics and Companion Diagnostics Development

15.18 Macro Trends in Personalized Medicine

15.19 Personalized Medicine and Companion Diagnostics: Industry SWOT Analysis

16. Business Trends in the Industry

16.1 Industry Consolidation

16.2 Breadth of Product Offering and Pricing

16.3 Government Regulation of Medical Devices

16.3.1 FDA Guidance on Drug Test Co-Development

16.4 Strategic Business and Marketing Considerations

16.5 Commercial Opportunities in Cancer Markers

16.5.1 Licensing and Intellectual Property Constraints and how they will Impact New Product Development

16.6 Moderators of Growth

16.6.1 Roadblocks to Integrating Cancer Biomarkers into Clinical Practice

16.7 Biotechnology Industry Trends

16.8 Pharmaceutical Industry Trends

16.9 Sales and Marketing Strategies for Tumor Marker Tests
16.9.1 North American Market
16.9.2 International Markets
16.9.2.1 Europe
16.9.2.2 Central and South America
16.9.2.3 Asia-Pacific
16.10 Product Commercialization
16.11 Reimbursement
16.12 Self Referral Rules
16.13 Health Insurance Portability and Accountability Act
16.14 Clinical Laboratory Improvement Amendments
16.15 In Vitro Diagnostic Directive and Medical Device Regulations
16.16 FDA’s Quality System Regulation
16.17 FDA’s OIVD on IVDMIAs
16.18 FDA Approval Process for Protein-Based Biomarkers
16.18.1 Classification of Protein-Based Biomarker Assays as Medical Devices
16.18.2 Clinical and Analytical Requirements for Biomarker Performance
16.18.3 Approval Process Workflow
16.19 Genetic Tests and Medical Records
16.19.1 Laws Against Genetic Discrimination
16.20 Medicare Reimbursement
16.20.1 Medicare Spending Trends
16.21 Global Drivers of Clinical Laboratory Testing
16.22 Global Outlook for Cancer Biomarkers
16.22.1 Which Companies are Utilizing Cutting-Edge Technologies to Develop, Validate and Implement Cancer Biomarkers for Clinical Use?
16.22.2 What Impediments Still Exist to Incorporating Promising Research into Clinical Practice?
16.22.3 Which Biomarkers Show the Most Promise for Approval?
16.22.4 How can Regulatory Oversight Drive Approval and Adoption of New Technologies?
16.22.5 Which Alliances Show the Greatest Synergy in Bringing Valid Biomarkers to Market?
16.22.6 Which Shared Technologies are Driving the Most Encouraging Development?
16.22.7 How Strategic Alliances and Interdisciplinary Involvement Drive Development and Implementation of Emerging Biomarker Technologies
16.23 Oncology Biomarker Qualification Initiative
16.24 FDA Critical Path
16.25 FDA Criteria for a Valid Biomarker

17. Companies Entering the Cancer Diagnostics Market with Novel Technology Platforms
17.1 Abbott Diagnostics
17.2 Affymetrix, Inc.
17.3 Agendia BV
17.4 Agensys, Inc. (Astellas Pharma US)
17.5 Agilent Technologies
17.6 Almac Group
17.7 AMDL, Inc.
17.8 Asuragen, Inc.
17.9 Aureon Laboratories, Inc.
17.10 Beckman Coulter, Inc.
17.11 Biocode Hycel S.A.
17.12 BioCurex, Inc.
17.13 Biomarker Technologies, LLC
17.14 Biomedical Diagnostics, LLC
17.15 Biomerica, Inc.
17.16 bioMérieux
17.17 Biomira, Inc. (Oncothyreon, Inc.)
17.18 Biomoda, Inc.
17.19 Bruker Daltonics, Inc.
17.20 Byk Gulden
17.21 Cangen Biotechnologies, Inc.
17.22 Caprion Proteomics
17.23 Celera Diagnostics
17.24 Cepheid
17.25 Clarient, Inc. (GE Healthcare)
17.26 Claros Diagnostics, Inc.
17.27 Clinical Data, Inc.: PGxHealth and Cogenics
17.28 Correlogic Systems, Inc.
17.29 CytoCore, Inc. (Formerly Molecular Diagnostics, Inc.)
17.30 Cytogen Corporation (now EUSA Pharma)
17.31 Dako (Agilent Technologies)
17.32 diaDexus, LLC
17.33 DiagnoCure, Inc.
17.34 DRG International, Inc.
17.35 EDP Biotech Corporation
17.36 Eisai Co., Ltd.
17.37 Eli Lilly & Co.
17.38 Epigenomics
17.39 Exact Sciences Corporation
17.40 Exagen Diagnostics, Inc.
17.41 Exigon
17.42 Gene Logic, Inc.
17.43 Genesis Genomics, Inc. (Mitomics)
17.44 GenMark Diagnostics
17.45 Genomic Health, Inc.
17.46 Gen-Probe, Inc. (now known as Hologic Gen-Probe)
17.47 Health Discovery Corporation
17.48 Ikonisys, Inc.
17.49 Illumina
17.50 Immunomedics, Inc.
17.51 Incyte Pharmaceuticals, Inc.
17.52 InterGenetics, Inc.
17.53 Ipsogen (Qiagen Marseille)
17.54 Janssen Diagnostics
17.55 LabCorp
17.56 Life Technologies Corporation (Thermo Fisher Scientific)
17.57 Matritech, Inc. (Alere)
17.58 Miraculins, Inc.
17.59 Mitsubishi Kagaku Medical
17.60 MolecularMD
17.61 Myriad Genetics, Inc.
17.62 NimbleGen Systems, Inc.
17.63 Northwest Biotherapeutics, Inc.
17.64 Oncotech, Inc. (Exiqon A/S)
17.65 Oncothryreon, Inc. (Formerly known as Biomira)
17.66 OPKO Health, Inc.
17.67 Orion Genomics
17.68 Oxford BioTherapeutics (Formerly Oxford Genome Sciences)
17.69 Panacea Pharmaceuticals, Inc.
17.70 Polymedco, Inc.
17.71 Power3 Medical Products
17.72 Qiagen N.V.
17.73 Roche Molecular Diagnostics
17.74 SensiGen, LLC (Sequenom Center for Molecular Medicine)
17.75 Siemens Healthcare Diagnostics, Inc.
17.76 Upstream Biosciences, Inc.
17.77 Ventana Medical Systems, Inc. (Part of the Roche Group)
17.78 Veridex, LLC (Janssen Diagnostics, LLC)
17.79 Vermillion, Inc. (Formerly Ciphergen)

Appendix 1: Cancer Biomarker Centers of Research
Appendix 2: Myriad Patents on Genes BRCA-1 and BRCA-2
Appendix 3: Cancer Markers Currently in Common Clinical Use
Appendix 4: International Federation of Gynecology and Obstetrics (FIGO) Staging System for Primary Carcinoma of the Ovary
Appendix 5: FDA Guidance for Industry: Pharmacogenomic Data Submission
A5.1 Introduction
A5.2 Background
A5.3 Submission Policy
A5.3.1 General Principles
A5.3.2 Specific Uses of Pharmacogenomic Data in Drug Development and Labeling
A5.3.3 Benefits of Voluntary Submissions to Sponsors and FDA
A5.4 Submission of Pharmacogenomic Data
A5.4.1 Submission of Pharmacogenomic Data During the IND Phase
A5.4.2 Submission of Pharmacogenomic Data to a New NDA, BLA or Supplement
A5.4.3 Submission to a Previously Approved NDA or BLA
A5.4.4 Compliance with 21 CFR Part 58
A5.4.5 Submission of Voluntary Genomic Data from Application-Independent Research
A5.5 Format and Content of a VGDS
A5.6 Process for Submitting Pharmacogenomic Data
A5.7 Agency Review of VGDSs
Appendix 6: E16 Biomarkers Related to Drug or Biotechnology Product Development: Context, Structure, and Format of Qualification Submissions
A6.1 Introduction
A6.2 Background
A6.3 Scope
A6.4 General Principles
A6.5 Structure of Biomarker Qualification Submissions

Glossary

LIST OF FIGURES:

Figure 3.1: Potential Market for Cancer Biomarkers
Figure 3.2: Segmentation of the Cancer Biomarkers Marketplace Based on Commercial Offerings—Products and Services
Figure 3.3: Geographical Distribution of Cancer Tumor Diagnostic Testing
Figure 3.4: Cancer Biomarkers Research Market, 2006-2016
Figure 3.5: Breast Cancer Biomarker Market Potential, 2010
Figure 3.6: Challenges in the Study or Utilization of Proteomic Cancer Biomarkers
Figure 3.7: Challenges in the Study or Utilization of Companion Diagnostic Cancer Biomarkers
Figure 3.8: Challenges in the Study or Utilization of Serum Cancer Markers
Figure 3.9: Top Unmet Needs in Commercial Products in the Cancer Biomarkers Space
Figure 5.1: Hybridization Process
Figure 5.2: FISH Test Procedure
Figure 5.3: Gene Expression Profiling
Figure 15.1: Strategic and Tactical Considerations for Co-Development of Companion Diagnostics
Figure 15.2: Global Market for Companion Diagnostics
Figure 15.3: Number of Companion Diagnostic Agreements, 2000-2013
Figure 15.4: Surface Binding Produces Phase Shifts that Increases the Diffraction Signal Intensity
Figure 15.5: Phase I and II Processes of Drug Metabolism
Figure 15.6: Human Phase I Enzymes
Figure 15.7: Human Phase II Enzymes
Figure 15.8: Hepatic Distribution of Human CYP450
Figure 15.9: Relative Contribution of CYP450 Enzymes to Drug Metabolism
Figure 15.10: Genetic Components Determine Drug Metabolism
Figure 15.11: From Genetic Content to Personalized Medicine
Figure 15.12: Remuneration for Diagnostics
Figure 15.13: Breakout of the Molecular Diagnostics Marketplace
Figure 15.14: Molecular Diagnostics Market Segmentation
Figure 15.15: Molecular Diagnostics Market Segmentation by Technology
Figure 15.16: Market Survey Respondent Demographics
Figure 15.17: Breakout of the Respondent Pool by Affiliation
Figure 15.18: Segmentation of the Personalized Medicine Market
Figure 15.19: Personalized Medicine Market Drivers
Figure 15.20: Challenges in the Personalized Medicine Space
Figure 16.1: Medicare Spending on Clinical Laboratory Services per Enrollee, 2003-2016

LIST OF TABLES:

Table 2.1: Cancer Biomarker Stakeholders
Table 3.1: Characteristics of Different Cancer Biomarker Types and Associated Market Opportunities
Table 3.2: Segmentation of the Cancer Biomarker Market by Type/Lineage of Cancer Biomarkers and Market Size
Table 3.3: In Vitro Cancer Marker Market Segments Worldwide, 2007-2012
Table 3.4: Worldwide Market Size in Dollar Volume for Tumor Marker Assays Product Market, 2009-2019
Table 3.5: U.S. Market Size in Dollar Volume for Tumor Marker Assays Product Market, 2009-2019
Table 3.6: Worldwide In Vitro Cancer Tumor Marker Diagnostics Market Size, 2009-2019
Table 3.7: U.S. In Vitro Cancer Tumor Marker Diagnostics Market Size, 2009-2019
Table 3.8: Japanese In Vitro Cancer Tumor Marker Diagnostics Market Size, 2009-2019
Table 3.9: European In Vitro Cancer Tumor Marker Diagnostics Market Size, 2009-2019
Table 3.10: Global Distribution of IVD Cancer Tumor Marker Diagnostic Testing, 2013
Table 3.11: Estimated Market Share of Major Competitors in U.S. Cancer Tumor Marker Diagnostics Market
Table 3.12: Major Presence in Cancer Tumor Marker Diagnostics Markets
Table 3.13: Worldwide CEA Sales, 2009-2019
Table 3.14: U.S. CEA Sales, 2009-2019
Table 3.15: Japan CEA Sales, 2009-2019
Table 3.16: Europe CEA Sales, 2009-2019
Table 3.17: Rest of the World CEA Sales, 2009-2019
Table 3.18: Worldwide PSA Sales 2009-2019
Table 3.19: U.S. PSA Sales 2009-2019
Table 3.20: Cancer Biomarkers Research Market Forecast, 2006-2016
Table 3.21: Cancer Biomarker Market Estimates by Tissue of Origin
Table 3.22: Companies Developing New Proteomic Cancer Biomarker Technology Platforms
Table 3.23: Uses of Molecular Diagnostics in Detection and Management of Cancer
Table 3.24: U.S. Cancer Diagnostic Testing Market Size, 2005-2016
Table 3.25: Market Opportunities for Cancer Biomarker Technology Platforms
Table 4.1: Use of Biomarkers in Clinical Use
Table 4.2: Use of Biomarkers in Cancer Research
Table 4.3: Currently Approved Targeted Therapies for Solid Malignancies and Their Molecular Targets
Table 4.4: Tumor Biomarkers Currently in Common Use
Table 4.5: Clinically Relevant Biomarkers
Table 4.6: Biomarkers for Monitoring Therapeutic Effectiveness and Resistance
Table 4.7: Biomarkers for Dose Response of Therapy
Table 4.8: Decision on Optimal Duration of Therapy
Table 5.1: Estimated New Female Breast Cancer Cases and Deaths by Age in the U.S., 2013
Table 5.2: BRCA Development Model
Table 5.3: BRCA Test Development and Commercialization
Table 5.4: BRACAnalysis
Table 5.5: Revenue for BRACAnalysis Risk Assessment Test, 2002-2013
Table 5.6: Key Players in the Breast Cancer Molecular Diagnostic Space
Table 5.7: Companies Offering IVD/MA Microarray Breast Cancer Biomarker Analysis
Table 5.8: GEArray DNA Microarrays and RT2 Profiler PCR Arrays
Table 5.9: Product Development Opportunities in Breast Cancer
Table 5.10: Concentration of Some Abundant Proteins, New Cancer Biomarkers Identified by SELDI-TOF and Classical Cancer Biomarkers in Serum
Table 5.11: Questions Related to Diagnostic SELDI-TOF Technology
Table 6.1: Worldwide CA-125 Sales, 2001-2018
Table 6.2: U.S. CA-125 Sales, 2001-2018
Table 6.3: Some Clinically Established Cancer Serum Markers Currently in Use for Cancer
Table 6.4: Pathophysiology of Ovarian Cancer and Characterization of Ovarian Epithelial Tumors
Table 7.1: Worldwide PSA Sales, 2000-2018
Table 7.2: U.S. PSA Sales, 2000-2018
Table 7.3: Molecular Gene Markers for Prostate Cancer
Table 8.1: Worldwide Bladder Cancer Marker Sales, 2001-2018
Table 8.2: U.S. Bladder Cancer Marker Sales, 2001-2018
Table 8.3: Worldwide NMP22 Sales, 2001-2018
Table 8.4: Summary of Matritech's Product Development Programs
Table 8.5: Opportunities for Bladder Cancer Biomarkers
Table 9.1: TNM Staging for CRC
Table 10.1: Genetic Diagnostics Market, 2004-2018
Table 13.1: Genomic and Proteomic Technologies
Table 14.1: Potential Benefits of Biomarkers as Companion Diagnostics
Table 14.2: Utility of Biomarker as Companion Diagnostics to Drug Development
Table 14.3: Device Submission Elements for the FDA
Table 14.4: Summary of Biomarker Use in the Commercialization of Novel Oncology Pharmacotherapeutics
Table 14.5: Pharmacoeconomic Challenges to the Implementation of Biomarkers as Companion Diagnostic Tests
Table 15.1: FDA Approved Companion Diagnostic Devices: In Vitro and Imaging Tools
Table 15.2: Personalized Medicine Industry SWOT Analysis
Table 15.3: Hurdles to Personalized Medicine and Companion Diagnostics Development
Table 15.4: Timeline of Impact in Areas of Personalized Medicine
Table 15.5: Impact of Personalized Medicine on Various Therapeutic Areas
Table 15.6: Percentage of Non-Responders in Various Drug Classes
Table 15.7: High Profile Drug Withdrawals from the Marketplace
Table 15.8: Drug Metabolism Drives Drug Efficacy/Toxicity
Table 15.9: Population Frequency of the Various Cytochromes
Table 15.10: Selected List of Personalized Medicine Tests
Table 15.11: Personalized Medicine and Companion Diagnostics Product Pipeline
Table 15.12: Marketed Personalized Therapies, 2013
Table 15.13: Members of the Personalized Medicine Coalition
Table 15.14: Various Molecular Diagnostics Technologies: Timeline for Impact
Table 15.15: Various Molecular Diagnostics Technologies: Impact on Different Therapeutic Areas in Personalized Medicine
Table 15.16: Technical Challenges in the Deployment for Personalized Medicine
Table 15.17: Classification of Diagnostics by Risk
Table 15.18: Areas in Personalized Medicine—Timeline of Impact
Table 15.19: Impact of Personalized Medicine on Various Therapeutic Areas
Table 15.20: Hurdles in Personalized Medicine and Companion Diagnostics Development in Various Therapeutic Areas
Table 15.21: Market Opportunities in Personalized Medicine
Table 15.22: Challenges for Market Adoption of the Various Personalized Medicine Tests
Table 15.23: Personalized Medicine Industry SWOT
Table 16.1: List and Discounted Prices for Abbott Tumor Marker Tests
Table 16.2: Increases in Total Allowed Charges for Laboratory Services per Enrollee, 2000-2016
Table 16.3: Incurred Reimbursement Amounts per Fee-for-Service for Laboratory Services per Enrollee, 2003-2016
Table 16.4: Medicare Part B Benefit Payments, 2003-2016
Table 17.1: Major GeneChip Instrument Products
Table 17.2: Major GeneChip Array and Reagent Products
Table 17.3: Gene Titan Products
Table 17.4: Gene Atlas Products
Table 17.5: Gene Atlas Products
Table 17.6: Opportunities for Biomarkers in Cancer Diagnosis and Treatment
Table 17.7: Tumor Diagnosis Immunoassay
Table 17.8: Tumor Diagnosis Radioimmunoassay
Table 17.9: Myriad Molecular Diagnostic Revenues, 2012 and 2013
Table 17.10: Roche Group Financial Figures—Net Sales by Business Sector, 2008-2013
Table 17.11: Roche Group Diagnostics Division—Net Sales by Geographic Region, 2012 and 2013
Table 17.12: Roche Group Financial Figures—Net Sales by Diagnostics Sub-Division, 2008-2013
Table A1.1: Team Descriptions
Table A3.1: List of FDA-Approved Protein Tumor Markers Currently Used in Clinical Practice

Order by Fax - using the form below
Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Biomarker Technology Platforms for Cancer Diagnoses and Therapies 2014
Web Address: http://www.researchandmarkets.com/reports/2989636/
Office Code: SCBR12WZ

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF)</td>
<td>USD 3400</td>
</tr>
<tr>
<td>Single User:</td>
<td></td>
</tr>
<tr>
<td>Electronic (PDF)</td>
<td>USD 6800</td>
</tr>
<tr>
<td>Site License:</td>
<td></td>
</tr>
<tr>
<td>Electronic (PDF)</td>
<td>USD 10200</td>
</tr>
<tr>
<td>Enterprisewide:</td>
<td></td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: Mr □ Mrs □ Dr □ Miss □ Ms □ Prof □
First Name: ___________________________ Last Name: ___________________________
Email Address: * ___________________________
Job Title: ___________________________
Organisation: ___________________________
Address: ___________________________
City: ___________________________
Postal / Zip Code: ___________________________
Country: ___________________________
Phone Number: ___________________________
Fax Number: ___________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: ___________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World